Cr Pharmaceutical
Cr Pharmaceutical, officially known as China Resources Pharmaceutical Group Limited, is a leading player in the pharmaceutical industry, headquartered in Shenzhen, China. Established in 1992, the company has expanded its operations across major regions, including Hong Kong and various provinces in mainland China. Specialising in the research, development, manufacturing, and distribution of pharmaceuticals, Cr Pharmaceutical offers a diverse range of products, including prescription medications, over-the-counter drugs, and healthcare products. Its commitment to innovation and quality has positioned it as a trusted name in the market, with notable achievements in drug development and a robust supply chain. With a strong market presence, Cr Pharmaceutical continues to enhance its reputation through strategic partnerships and a focus on sustainable practices, making significant contributions to the healthcare sector both domestically and internationally.
DitchCarbon Score
How does Cr Pharmaceutical's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Medical Instruments industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Cr Pharmaceutical's score of 36 is higher than 72% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Cr Pharmaceutical's reported carbon emissions
In 2023, Cr Pharmaceutical reported total carbon emissions of approximately 725,649 tonnes CO2e, with Scope 1 emissions accounting for about 170,536 tonnes CO2e and Scope 2 emissions at around 555,112 tonnes CO2e. This marks a significant commitment to transparency in their climate impact, although specific reduction targets or initiatives have not been disclosed. Over the years, Cr Pharmaceutical's emissions have fluctuated, with a notable increase from 2022, where total emissions were about 774,981 tonnes CO2e. The company has not established formal reduction targets under frameworks such as the Science Based Targets initiative (SBTi) or the Carbon Disclosure Project (CDP), indicating a potential area for future development in their climate strategy. The emissions data reflects a broader industry context where pharmaceutical companies are increasingly scrutinised for their environmental impact. Cr Pharmaceutical's commitment to monitoring and reporting emissions is a step towards greater accountability, but the absence of specific reduction initiatives suggests that further action may be necessary to align with global climate goals.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
Add to project2018 | 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|---|
| Scope 1 | 541,956,860 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
| Scope 2 | - | - | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
| Scope 3 | - | - | 00,000,000 | 00,000,000 | 00,000,000 | - |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Cr Pharmaceutical is not committed to any reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
